DrugPatentWatch Database Preview
VELETRI Drug Profile
When do Veletri patents expire, and when can generic versions of Veletri launch?
Veletri is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has eighteen patent family members in fourteen countries.
The generic ingredient in VELETRI is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.
Summary for VELETRI
| International Patents: | 18 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 20 |
| Clinical Trials: | 1 |
| Patent Applications: | 599 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VELETRI |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VELETRI |
| DailyMed Link: | VELETRI at DailyMed |
Recent Clinical Trials for VELETRI
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duke University | Phase 4 |
Recent Litigation for VELETRI
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| ACTELION PHARMACEUTICALS LTD. v. SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-07-07 |
Pharmacology for VELETRI
| Drug Class | Prostacycline Vasodilator |
| Physiological Effect | Vasodilation |
Synonyms for VELETRI
| (5Z,13E,8R,9S,11R,12R,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid sodium salt |
| (5Z,9|A,11|A,13E,15S)-6,9-epoxy-11,15-Dihydroxy-prosta-5,13-dien-1-oic Acid Sodium Salt |
| 4K04IQ1OF4 |
| 4UA76 |
| 61849-14-7 |
| 91284-07-0 |
| AC1O4BXH |
| ACT-385781A |
| AKOS024457370 |
| BML1-F10 |
| C20H31NaO5 |
| C20H31O5.Na |
| CAS-61849-14-7 |
| CHEMBL962 |
| Cyclo-Prostin |
| DSSTox_CID_26617 |
| DSSTox_GSID_46617 |
| DSSTox_RID_81769 |
| DTXSID3046617 |
| EINECS 263-273-7 |
| Epoprostenol sodium |
| Epoprostenol sodium [USAN:BAN] |
| Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer |
| Epoprostenolsodium |
| Flolan |
| Floran |
| HMS1361K18 |
| HMS3648L14 |
| LMHIPJMTZHDKEW-XQYLJSSYSA-M |
| LS-176206 |
| MolPort-006-132-470 |
| NCGC00167427-01 |
| Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (5Z,9alpha,11alpha,13E,15S)- |
| prostacyclin |
| Prostacyclin sodium |
| Prostacyclin sodium salt |
| PROSTAGLANDIN I2 Na |
| Prostaglandin I2 sodium |
| Prostaglandin X sodium |
| SCHEMBL41344 |
| Sodium (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dien-1-oate |
| sodium (5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate |
| Sodium (Z)-(3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valerate |
| sodium (Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-enyl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoate |
| Sodium prostacyclin |
| Tox21_112431 |
| U 53,217A |
| U-53,217A |
| U-53217A |
| UNII-4K04IQ1OF4 |
| V0155 |
Paragraph IV (Patent) Challenges for VELETRI
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| VELETRI | INJECTABLE;INJECTION | epoprostenol sodium | 022260 | 2017-03-31 |
US Patents and Regulatory Information for VELETRI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion Pharms Ltd | VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260-002 | Jun 28, 2012 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Actelion Pharms Ltd | VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260-001 | Jun 27, 2008 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Actelion Pharms Ltd | VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260-002 | Jun 28, 2012 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Actelion Pharms Ltd | VELETRI | epoprostenol sodium | INJECTABLE;INJECTION | 022260-001 | Jun 27, 2008 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VELETRI
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 1993557 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2007092343 | Start Trial |
| South Korea | 20090004867 | Start Trial |
| Canada | 2641393 | Start Trial |
| Cyprus | 1117128 | Start Trial |
| European Patent Office | 1993557 | Start Trial |
| Japan | 5415771 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
